The FDA combination therapy approval of dolutegravir and rilpivirine is indicated for Older people with HIV-1 bacterial infections whose virus is now suppressed (Administration of large doses of tenofovir has long been described to make bone toxicity claimed as osteomalacia and decreased bone mineral density and to provide some degree of renal toxi